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Middle East respiratory syndrome coronavirus (MERS-CoV) is a recently reported virus that is associated
with severe, life threatening and rapidly spreading primarily respiratory illness called the Middle East
respiratory syndrome. MERS-CoV possesses a unique positive-sense single-stranded RNA and can un-
dergo rapid mutation in the viral genome. This results in antigenic switching and genetic variation,
finally leading to the emergence of novel and new MERS-CoV subtypes which are uncontrollable by
vaccines. Researchers are also finding difficulties to sort out therapeutic intervention strategies for MERS-
CoV. This virus can spread from human to human, but transmission from dromedary camels to humans
plays a crucial epidemiological significance. Dromedary camel acts as “gene mixing vessels” for MERS-
CoV and these virus particles undergo rapid change in them. Viral receptors called dipeptidyl pepti-
dase-4 are important receptors for attachment and spread of MERS-CoV in humans. The current method
of laboratory confirmation is through real-time polymerase chain reaction on bronchoalveolar lavage,
sputum and tracheal aspirates. Unfortunately, till today there are no definite anti-viral drugs available for
MERS-CoV.
Copyright © 2017 Institut Pertanian Bogor. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV) is a
unique positive-sense single-stranded RNA (þssRNA) virus
belonging to the genus Betacoronavirus (World Health
Organization, 2014). Previously, it was called novel coronavirus
2012 because it was isolated in 2012 by genomic sequencing from
sputum of a patient, during the 2012 outbreak of new flu (Zaki et al.
2012).
Until August 2015, MERS-CoV outbreaks were reported in more
than 21 nations like Saudi Arabia, Jordan, Egypt, Qatar, UAE, Turkey,
Kuwait, Oman, Bangladesh, Indonesia, Algeria, South Korea,
Philippines, Thailand, USA, UK and Austria (Abdullah et al. 2016).
According to the European Center for Disease Prevention and(K. Subbaram), hema_
heh@yahoo.com (M. Khalil
nian Bogor.
r. Production and hosting by ElsControl, it was estimated that out of a total of 1082MERS-CoV cases,
there were 439 deaths thereby mortality rate leading to whooping
41% (Haagmans et al. 2015). As per the World Health
Organization estimates, the fatality rate surged to 37%. MERS-CoV
patients have acquired this deadly infection through various sour-
ces, namely, infected humans, camels, bats, other domesticated
animals and pets (World Health Organization, 2015). The very na-
ture and special feature of coronavirus is its ability to undergo rapid
genetic rearrangement and profound molecular variation in its
ssRNA. This rearrangement and variation of the viral genome
resulting in new antigenic subtypes, leads to difficulties in devel-
oping vaccines and therapeutic interventions (Chu et al. 2016).
Hence, MERS-CoV poses serious threat not only to the Middle East
region, but also throughout the world, as a whole.
Genomes of MERS-CoV are phylogenetically grouped into clade
A and clade B. Initially, reported MERS-CoV cases belonged to clade
A (Jordan-N3/2012), recently, the newly reported cases were shown
to be genetically different, as such, they were named as clade B.
Based on molecular, genetic and antigenic studies, it was estab-
lished that MERS-CoV is unique and different from severe acuteevier B.V. This is an open access article under the CC BY-NC-ND license (http://
K. Subbaram, et al54respiratory syndrome (SARS) coronavirus and common cold coro-
naviruses. Because of this fact, earlier MERS-CoV was called “Saudi
SARS” (Azhar et al. 2016). This notorious virus was first identified
and isolated in Saudi Arabia by Dr Ali Mohamed Zaki from a patient
suffering from pneumonia-like illness, and these isolates exhibited
cytopathic effects like syncytia formation. Through molecular clock
analysis, zoonotic transmission was established from dromedary
camels (Camelus dromedaries), particularly prevailing in Middle
East countries.
2. Virology of MERS-CoV
2.1. Molecular Virulence
Both MERS-CoV and SARS coronavirus have similar þssRNA in
their genome.
This ssRNA in MERS-CoV encodes structural proteins (SPs),
membrane protein (M), envelope (E), nucleocapsid (N), two non-
structural replicase polyproteins (ORF1a and ORF1b) and spike (S)
(Reusken et al. 2016). The two non-structural proteins (NSPs)
initiate genomic replication and RNA synthesis. The huge replicase
gene surrounds 50 proximal side of RNA genome. Translation of
ORF1a gives rise to polyprotein 1a (pp1a) and ribosomal frame
shifting makes translation of ORF1b to give pp1ab. MERS-CoV uses
one or two papain-like protease to release NSPs. It is established
that MERS-CoV possesses 16 NSPs (Firth and Brierley, 2015).
Viral components like NSPs, SPs, M, E, N, S and other proteins,
glycoproteins and enzymes play a crucial role in virulence in
establishing and exaggerating the disease (Figure 1).Figure 1. Molecular structure of MERS-CoV. MERS-CoV ¼ Middle East respiratory syndrom
(Photo courtesy Dr Ian M Mackay, PhD)MERS-CoV's E protein is responsible for the attachment of virus
particles to host cell receptors. S protein is in charge of fusion and
entry in to the respiratory epithelia (Kilianski et al. 2016).
Virus-induced proteases help viral particles to spread to lower
parts of the lungs, thus enhancing the severity of the infection. It
results in inflammation and suppression of anti-viral interferons
(IFN). At this point of the infection, there is excessive anti-viral
immune responses like interleukins (IL-6, IL-8 and TNF-a), humoral
IgG and IgM are inefficient to control the viral spread and replica-
tion in the lungs. The very nature of MERS-CoV virus ability to
overcome and suppress host immune challenge is due to
its þssRNA, viral SPs and NSPs (Mielech et al. 2016).
2.2. Pathogenesis and symptomatology
MERS-CoV exhibits its degree of pathogenicity based on the
host. It elicits maximum pathogenic potential, especially in
humans. This is due to the fact that MERS-CoV shows a strong
tropism for bronchial non-ciliated epithelia. During this time, it is
proved that virus also arrests host bronchial IFN synthesis
(Coleman et al. 2015; Mielech et al. 2016). At this juncture, it should
be noted that most of other viruses causing respiratory diseases
attack and damage epithelial cilia, including influenza type A.
Studies revealed that cellular receptors for MERS-CoV is exopepti-
dase (angiotensin converting enzyme 2) (Coleman et al. 2015).
Moreover, it was found that neutralization of angiotensin con-
verting enzyme 2 by specific antibodies did not arrest the spread of
infection into bronchus and lung alveolus. Extensive studies
showed that another functional cellular receptors called dipeptidyl
peptidase-4 were also involved in the severity of disease spread ine coronavirus.
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for dipeptidyl peptidase-4 are also located in nephrons of kidneys
and heart. During the acute stage of the MERS-CoV infection, there
is severe viremia, leading to the spread of MERS-CoV virus particles
in blood stream. At this point, MERS-CoV exhibits the hall mark of
infection leading to not only to the damage of lungs but also kid-
neys and heart, thereby resulting in respiratory, renal and cardiac
failure, ultimately leading to coma and death (vanBoheemen et al.
2016). The severity is worsened by concurrent secondary bacte-
rial infections. Recent research showed that bacterial infections due
to Staphylococcus aureus, Group A Streptococcus, Streptococcus
pneumoniae and Haemophilus influenzae type b augment the
pathogenic potential of MERS-CoV, particularly in humans. These
bacteria particularly dwell in the oral cavities, tonsils and pharynx
of humans (Lau et al. 2016). Another interesting fact is that the
reservoir host dromedary camels and other animals do not exhibit
the presence of dipeptidyl peptidase-4 receptors in their kidneys
and heart. In humans, after the entry of MERS-CoV viral particles in
to lung alveoles, alveolar macrophages fail to contain the spread of
infection. The strong host cellular immune response and cytokine
release lead to inflammation and fluid accumulation in lungs. This
will result in the characteristic symptoms of MERS-CoV; high fever,
chills, rigors, severe cough, dyspnoea and hypovolemic shock (Lin
et al. 2016). Many patients exhibited common symptoms of pneu-
monia, whereas a significant number of patients expressed symp-
toms of chronic obstructive pulmonary syndrome like disease.
Another large number of patients also revealed laryngotracheo-
bronchitis, which is called “croup”. The patterns of disease due to
MERS-CoV also differed among different age groups. Clinical cases,
morbidity andmortality rates due toMERS-CoV infections are more
common and high (80%) in the age group of 35e45 years. Aston-
ishingly, the severity of MERS-CoV is lower (40%) in the higher age
groups, particularly above 55 years (Lei et al. 2015).
2.3. Epidemiology
Epidemiology and mode of spread of MERS-CoV play a crucial
role in morbidity and fatality due to these life-threatening viruses.
Different ways of transmission of MERS-CoV have been docu-
mented (Corman et al. 2015). They include dromedary camel to
human mode, bats to camels, among camels, cattle to man, dogs to
humans, cats to man, bats to humans and finally man to man
transmission. Human to human spread is very effective and com-
mon in close contacts and crowded surroundings. Nosocomial,
hospital-borne outbreaks have also been reported in many in-
stances. There have been reported incidences of spread from pa-
tients to health care workers (Song et al. 2015). In MERS-CoV
epidemiology, dromedary camels play an important role because
these animals act as reservoir host. Dromedary camels also act as
“gene mixing vessels”. When two different strains of MERS-CoV,
from two different sources, infect dromedary camels, these two
genetically different MERS-CoV exchange theirþssRNA resulting in
the development (mutation) of new subtypes of MERS-CoV. The
stunning features of these new subtypes of MERS-CoV have new
antigens and novel virulence genes. In Saudi Arabia, there were
possible cases of human transmission after drinking camel milk.
But, there are no cases documented in humans through ingestion of
camel meat (de Wit et al. 2016).
2.4. Recent laboratory testing techniques
Patients suffering from MERS exhibited low white blood cell
count in particular of low lymphocytes. Confirmation and rapid
molecular testing can be performed using real-time polymerase
chain reaction (RT-PCR) test. RT-PCR testing can be performed on
bronchoalveolar lavage, sputum and tracheal aspirates. Serological
test like immunofluorescence technique (IFT) is also useful. But, themain issue with IFT is many other serologically related viruses may
cross-react with MERS-CoV antibodies. So, IFT is unsuitable for
confirmation. World Health Organization recommends RT-PCR for
the confirmation of MERS-CoV in clinical samples (Baez-Santos
et al. 2014).2.5. Prevention and treatment
Because themain transmission is through camels, people should
be advised to handle camels with precautions, especially camels
with severe nasal discharge. Other general health care measures
should be taken to arrest nosocomial hospital-borne MERS-CoV
outbreaks. For the treatment of MERS-CoV cases, administration
of ribavirin and IFN-a2b was found to be promising, but not very
effective. Researchers are recently investigating many ways to
overcome the outbreak of MERS-CoV. Many drugs are under eval-
uation (IFN, chloroquine, chlorpromazine, loperamide, camostat,
mycophenolic acid and lopinavir (de Wit et al. 2016).3. Conclusion
MERS-CoV causes severe, life threatening and rapidly spreading
Middle East respiratory syndrome not only in Middle East region,
but throughout the world. Dromedary camels and bats play an
important role in the spread of MERS-CoV. Several nosocomial in-
fections due to MERS-CoV have also been reported worldwide.
Several viral SPs and NSPs are critical for the molecular virulence of
MERS-CoV. Because of the þssRNA, MERS-CoV can undergo mo-
lecular rearrangement leading to antigenic change, genetic varia-
tion and mutation. This attributes to the emergence of new and
novel subtypes of MERS-CoV in the human populations. These
unique subtypes are difficult to control by vaccinations and thera-
peutic intervention strategies. Another important issue faced by
scientists and molecular virologists is related to these new MERS-
CoV viral particles which possess enhanced molecular virulence,
thus leading to increased pathogenicity and a more rapid spread
than their parental strains. Studies revealed that dromedary camels
act as “gene mixing vessels” for MERS-CoV. Prevention is mainly
based on avoiding contact with dromedary camels and focussing on
nosocomial infection outbreaks. Researchers are constantly trying
to develop anti-viral drugs to combat MERS-CoV, but till today
there is no breakthrough. The perspective of what canwe expect in
the future of this field is developing effective vaccine, conducting
detailed studies on molecular research on mechanism of mutation
and genetic recombination occurring in MERS-CoV.Conflict of interest
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